Showing results (1571-1580 of 1,669) with videos related to

Sort By:
Pageof 167
Blood|November 6, 2007
In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinibJamshid S Khorashad, Dragana Milojkovic, Puja Mehta, et al.
British Journal of Haematology|October 15, 2013
A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemiaJacob Grinfeld, Gareth Gerrard, Mary Alikian, et al.
Leukemia|March 14, 2009
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemiaA Hochhaus, S G O'Brien, F Guilhot, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|July 5, 2011
EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedureKatayoun Rezvani, Edward J Kanfer, David Marin, et al.
Medrxiv : the Preprint Server for Health Sciences|January 3, 2024
Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessmentDarren M Weber, Steven W Taylor, Robert J Lagier, et al.
Frontiers in Neurology|April 10, 2024
Clinical utility of plasma Aβ42/40 ratio by LC-MS/MS in Alzheimer's disease assessmentDarren M Weber, Steven W Taylor, Robert J Lagier, et al.
Blood|August 22, 2008
European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poorDavid Marin, Dragana Milojkovic, Eduardo Olavarria, et al.
Kidney International|March 1, 1996
OKT3 prophylaxis in renal grafts with prolonged cold ischemia times: association with improvement in long-term survivalD Abramowicz, D J Norman, P Vereerstraeten, et al.
Blood|March 23, 2010
Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phaseJirí Pavlů, Andrea K Kew, Beatrice Taylor-Roberts, et al.
Blood|September 22, 2010
EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitorsMustafa Daghistani, David Marin, Jamshid Sorouri Khorashad, et al.
Pageof 167